تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
31.62 US$
+0.73 US$ · +2.36%
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
الإغلاق السابق
31.62 US$
+0.73 US$ · +2.36%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
نطاق اليوم
السعر الحالي 31.62 US$
نطاق 52 أسبوعًا
السعر الحالي 31.62 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
نطاق اليوم
السعر الحالي 31.62 US$
نطاق 52 أسبوعًا
السعر الحالي 31.62 US$
| البند (USD) | السنة المالية 2025 |
|---|---|
| البحث والتطوير | 59.63 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 10.49 مليون USD |
| نفقات التشغيل | 70.12 مليون USD |
| دخل الفوائد | 1.97 مليون USD |
| الاستهلاك والإطفاء | 304 ألف USD |
| الدخل التشغيلي | −70.12 مليون USD |
| صافي الدخل | −63.91 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
51.40 US$
ارتفاع محتمل بنسبة 62.56%صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI25.4 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
State Street SPDR S&P Biotech ETFXBI16.12 مليون0.16%9.87 مليار USD0.35%153.77 US$+3.00%
iShares Russell 2000 ETFIWM15.92 مليون0.02%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF9.41 مليون0.01%95.4 مليار USD0.05%235 US$+0.80%
iShares Russell 2000 Growth ETFIWO3.42 مليون0.02%13.92 مليار USD0.24%356.78 US$+0.94%
Schwab U.S. Small-Cap ETFSCHA2.88 مليون0.01%21.82 مليار USD0.03%32.79 US$+0.40%
Fidelity Fundamental Small-Mid Cap ETFFFSM1.66 مليون0.10%1.44 مليار USD0.43%34.13 US$+0.62%
T. Rowe Price Small-Mid Cap ETFTMSL1.22 مليون0.04%3.09 مليار USD0.55%41.18 US$+0.59%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAFidelity Fundamental Small-Mid Cap ETFFFSMT. Rowe Price Small-Mid Cap ETFTMSLالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
